Abstract

Metastatic breast cancer (mBC) continues to be an incurable disease, but modern drug therapy, associated with the steady extension of the arsenal of active cytostatic drugs and the development of new treatment options, provides the long-term control of tumor growth, transforming into chronic pathology. Nab-paclitaxel (nanodispersed albumin-bound paclitaxel) is one of such options. This innovative dosage form provides the active transport of the drug through the vascular endothelium with the creation of the high concentration in the tumor tissue. Clinical trial of nab-paclitaxel compared with traditional taxanes (paclitaxel and docetaxel) have demonstrated high efficiency of a new drug both in the general population and in the selected subgroups of patients, including treated with anthracyclines, patients with invasive disease, damages of the visceral organs, younger patients and others. Nab-paclitaxel proved to act in patients treated with taxanes, the physician can use this drug one again and thus we have another line of therapy. Nab-paclitaxel can be effectively and safely combined with trastuzumab in patients with mBC associated with HER2+. In addition, the drug because of the unique formula does not cause hypersensitivity reactions and differs from traditional taxanes of the variant of application. No need for premedication with dexamethasone let us appoint the drug in patients with comorbid conditions: severe arterial hypertension, diabetes, gastric and duodenal ulcers and others. High safety of nab-paclitaxel was approved in elderly patients as well.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call